Travere Therapeutics Inc’s recent filing unveils that its CHIEF MEDICAL OFFICER Inrig Jula unloaded Company’s shares for reported $39461.0 on Jan 03 ’25. In the deal valued at $19.10 per share,2,066 shares were sold. As a result of this transaction, Inrig Jula now holds 59,883 shares worth roughly $1.11 million.
Then, Inrig Jula sold 440 shares, generating $8,254 in total proceeds. Upon selling the shares at $18.76, the CHIEF MEDICAL OFFICER now owns 59,443 shares.
Before that, Calvin Sandra sold 15,000 shares. Travere Therapeutics Inc shares valued at $258,277 were divested by the SVP, CHIEF ACCOUNTING OFFICER at a price of $17.22 per share. As a result of the transaction, Calvin Sandra now holds 54,927 shares, worth roughly $1.02 million.
Cantor Fitzgerald initiated its Travere Therapeutics Inc [TVTX] rating to an Overweight in a research note published recently. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who increased its forecast for the stock in late October from “an Equal weight” to “an Overweight”. Scotiabank began covering TVTX with “Sector outperform” recommendation on October 16, 2024. Guggenheim revised its rating on September 09, 2024. It rated TVTX as “a Buy” which previously was an “a Neutral”.
Price Performance Review of TVTX
On Monday, Travere Therapeutics Inc [NASDAQ:TVTX] saw its stock jump 2.76% to $18.59. Over the last five days, the stock has lost -1.43%. Travere Therapeutics Inc shares have risen nearly 6.72% since the year began. Nevertheless, the stocks have risen 98.40% over the past one year. While a 52-week high of $20.33 was reached on 01/08/25, a 52-week low of $5.12 was recorded on 01/13/25. SMA at 50 days reached $18.20, while 200 days put it at $11.85.
Levels Of Support And Resistance For TVTX Stock
The 24-hour chart illustrates a support level at 17.80, which if violated will result in even more drops to 17.02. On the upside, there is a resistance level at 19.05. A further resistance level may holdings at 19.52. The Relative Strength Index (RSI) on the 14-day chart is 54.38, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.52, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 27.52%. Stochastics %K at 71.40% indicates the stock is a holding.
How much short interest is there in Travere Therapeutics Inc?
A steep rise in short interest was recorded in Travere Therapeutics Inc stocks on 2024-12-31, growing by 1.14 million shares to a total of 8.72 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 7.57 million shares. There was a rise of 13.13%, which implies that there is a positive sentiment for the stock.
